2. Search Result
Search Result
Results for "

human lung cancer

" in MedChemExpress (MCE) Product Catalog:

317

Inhibitors & Agonists

5

Fluorescent Dyes

6

Biochemical Assay Reagents

11

Peptides

1

MCE Kits

56

Inhibitory Antibodies

76

Natural
Products

5

Recombinant Proteins

10

Isotope-Labeled Compounds

2

Antibodies

1

Click Chemistry

3

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0162
    Luteolin
    Maximum Cited Publications
    89 Publications Verification

    Luteoline; Luteolol; Digitoflavone

    		 Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite Inflammation/Immunology Cancer
    Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells .
    Luteolin
  • HY-P9903
    Nivolumab
    Maximum Cited Publications
    23 Publications Verification

    BMS-936558; ONO-4538; MDX-1106

    		 PD-1/PD-L1 Infection Cancer
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
    Nivolumab
  • HY-126477
    NNK
    2 Publications Verification

    		 Endogenous Metabolite Cancer
    NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser 70 and c-Myc at Thr 58 and Ser 62 through activation of both ERK1/2 and PKCα . NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure .
    NNK
  • HY-115385
    Lumichrome
    2 Publications Verification

    		 Apoptosis MDM-2/p53 Akt β-catenin Nuclear Factor of activated T Cells (NFAT) NF-κB ERK p38 MAPK Metabolic Disease Cancer
    Lumichrome, a photodegradation product of Riboflavin, is an endogenous compound in humans. Lumichrome inhibits human lung cancer cell growth and induces apoptosis via a p53-dependent mechanism. Lumichrom is the inhibitor for AKT/β-catenin signaling pathway .
    Lumichrome
  • HY-P9964
    Necitumumab

    11F8; IMC-11F8; LY3012211

    		 EGFR Cancer
    Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
    Necitumumab
  • HY-116424
    DYn-2

    Anti-dynamin II

    		 Biochemical Assay Reagents Cancer
    DYn-2 (Anti-dynamin II) is a chemoselective sulfenylated protein probe. DYn-2 binds to sulfenylated proteins with chemoselectivity, enabling the detection of such proteins. DYn-2 can detect differences in intracellular sulfenylation rates. DYn-2 can be used in human cancer research, including studies on breast cancer and lung cancer .
    DYn-2
  • HY-156617A
    (αR)-Cyclopropaneacetamide-Exatecan

    SHR169265

    		 ADC Payload Topoisomerase Cancer
    (αR)-Cyclopropaneacetamide-Exatecan (SHR169265) is a DNA Topoisomerase I inhibitor with enhanced membrane permeability (with an IC50 of 1.34 μM against the human DNA Topoisomerase I). (αR)-Cyclopropaneacetamide-Exatecan exerts cytotoxic effects by inhibiting the enzymatic activity of Topoisomerase I, and this anticancer effect is independent of the expression level of HER2. (αR)-Cyclopropaneacetamide-Exatecan is an ADC Cytotoxin derived from Exatecan (HY-13631), which can be used in research related to advanced cancers such as breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer .
    (αR)-Cyclopropaneacetamide-Exatecan
  • HY-131498
    MOCAc-PLGL(Dpa)AR

    Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2

    		 Fluorescent Dye MMP Cancer
    MOCAc-PLGL (Dpa) AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) is a synthetic fluorescent substrate mainly used for in vitro enzymatic activity assays of MMP-7 (detection at 393 nm after excitation at 328 nm). MOCAc-PLGL (Dpa) AR is specifically cleaved and hydrolyzed by MMP-7 at the Gly-Leu peptide bond, allowing enzymatic activity to be monitored via fluorometry or HPLC (DMSO is usually added to ensure sufficient dissolution when determining kinetic parameters). MOCAc-PLGL (Dpa) AR is used to accurately evaluate the catalytic activity and pH dependence of recombinant mature human MMP-7 in vitro. MOCAc-PLGL (Dpa) AR is suitable for research on the mechanisms of tumor metastasis and invasion, particularly in fields such as prostate cancer, colon cancer, lung cancer and breast cancer .\n
    MOCAc-PLGL(Dpa)AR
  • HY-P10375
    BMS-986189

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 .
    BMS-986189
  • HY-164729
    FZ-AD005

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
    FZ-AD005
  • HY-13241A
    Ralimetinib
    10+ Cited Publications

    LY2228820

    		 p38 MAPK Autophagy Cancer
    Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .
    Ralimetinib
  • HY-P99189
    Cixutumumab

    IMC-A12; NSC742460

    		 IGF-1R Cancer
    Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
    Cixutumumab
  • HY-16662
    Oncrasin-1

    		DNA/RNA Synthesis Ras Apoptosis Cancer
    Oncrasin-1 is an RNA polymerase inhibitor. Oncrasin-1 suppresses the phosphorylation of the largest subunit of RNA polymerase II and the expression of intronless reporter genes in sensitive cells. Oncrasin-1 effectively kills various human lung cancer cells with K-Ras mutations. Oncrasin-1 leads to coaggregation of PKCι and splicing factors into megaspliceosomes. Oncrasin-1 induces malfunction in the RNA processing machinery. Oncrasin-1 is an anti-cancer agent and can therefore be studied in research for lung cancer .
    Oncrasin-1
  • HY-113221
    Isovalerylcarnitine

    		Proteasome Endogenous Metabolite Apoptosis Metabolic Disease Cancer
    Isovalerylcarnitine is a metabolite of leucine. Isovalerylcarnitine can specifically activate calpain in human neutrophils. Isovalerylcarnitine inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine are negatively correlated with reduced lung cancer risk .
    Isovalerylcarnitine
  • HY-Y0030
    3-Hydroxypicolinic acid

    3-hydroxypyridine-2-carboxylic acid

    		 Biochemical Assay Reagents Drug Intermediate Infection Cancer
    3-Hydroxypicolinic acid is a heterocyclic carboxylic acid ligand and cytotoxin, with a MIC90 of >25 μg/mL against Mycobacterium tuberculosis H37Rv. 3-Hydroxypicolinic acid inhibits the growth of cancer cells and normal fibroblasts. 3-Hydroxypicolinic acid is applicable to research related to chronic myeloid leukemia, human lung adenocarcinoma, and tuberculosis .
    3-Hydroxypicolinic acid
  • HY-P5098
    E(c(RGDfK))2

    		Integrin Neurological Disease Cancer
    E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
    E(c(RGDfK))2
  • HY-153873
    MSU38225

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Cancer
    MSU38225 is an Nrf-2 inhibitor that increases levels of reactive oxygen species (ROS). MSU38225 inhibits the growth of human lung cancer cells and enhances the sensitivity of human lung cancer cells to chemotherapy in vitro and in vivo. MSU38225 can be used in cancer research .
    MSU38225
  • HY-P99296
    Intetumumab

    CNTO 95; Anti-human CD51 Recombinant Antibody

    		 Integrin Apoptosis Cancer
    Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
    Intetumumab
  • HY-P991372
    Anti-TROP2 Antibody

    RN927C antibody

    		 TROP2 Cancer
    Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .
    Anti-TROP2 Antibody
  • HY-N0162R
    Luteolin (Standard)
    Maximum Cited Publications
    89 Publications Verification

    Luteoline(Standard); Luteolol(Standard); Digitoflavone (Standard)

    		 Reference Standards Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite Inflammation/Immunology Cancer
    Luteolin (Standard) is the analytical standard of Luteolin. This product is intended for research and analytical applications. Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells .
    Luteolin (Standard)
  • HY-153937
    Skp2 inhibitor 2

    		E1/E2/E3 Enzyme Cancer
    Skp2 inhibitor 2 is a Skp2-Cks1 protein-protein interaction inhibitor with a human IC50 of 0.57 μM. Skp2 inhibitor 2 binds to Skp2 at the interaction interface to block Skp2-Cks1 complex formation. Skp2 inhibitor 2 can be used for the research of gastric cancer, non-small cell lung cancer, breast cancer, prostate cancer .
    Skp2 inhibitor 2
  • HY-W002016
    Phthalazine

    		Reactive Oxygen Species (ROS) Cancer
    Phthalazine is a substrate for human aldehyde oxidase 1, which can lead to the production of ROS and subsequent enzyme inactivation. Phthalazine is a nitrogen-containing organic heterocyclic compound. Phthalazine exhibits antitumor activity in blood cancer, breast cancer, colon cancer, lung cancer and renal cancer .
    Phthalazine
  • HY-P5542
    Vicatertide

    SB-01; Peniel 2000

    		 Factor Xa TGF-beta/Smad Inflammation/Immunology
    Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a Ka of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .
    Vicatertide
  • HY-P99858
    Domvanalimab

    AB154

    		 Transmembrane Glycoprotein Cancer
    Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
    Domvanalimab
  • HY-P991196
    Anti-CD24 Antibody (SWA11)

    		Transmembrane Glycoprotein Cancer
    Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-CD24 Antibody (SWA11)
  • HY-147259
    Dalmelitinib

    		c-Met/HGFR Cancer
    Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .
    Dalmelitinib
  • HY-131344
    mTOR inhibitor-8

    		mTOR Autophagy Cancer
    mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .
    mTOR inhibitor-8
  • HY-145542
    Isovalerylcarnitine chloride

    		Endogenous Metabolite Proteasome Apoptosis Metabolic Disease Cancer
    Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk .
    Isovalerylcarnitine chloride
  • HY-115590
    JP-11646

    		Pim Caspase Apoptosis Necroptosis PARP NF-κB Cancer
    JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 (IC50 = 0.5 nM). JP11646 is freely reversible and ATP non-competitive. JP-11646 results in a decrease of PIM1, 2, and 3 mRNA. JP-11646 can effectively inhibit cell viability in small cell lung cancer (SCLC) and large cell neuroendocrine carcinomas of the lung (LCNEC). JP-11646 can cause a decrease in p-4EBP-1 protein, increasing the cleavage of caspases while decreasing caspase-3. JP-11646 induces apoptosis or necroptosis in cells. JP-11646 leads to reductions in MYC paralogs. JP-11646 can be used for the study of SCLC, LCNEC, human acute leukemia (AML), multiple myeloma (MM), and triple-negative breast cancer (TNBC) .
    JP-11646
  • HY-124321
    Metralindole hydrochloride

    		CDK Cancer
    Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .
    Metralindole hydrochloride
  • HY-Y1269D
    Ammonium chloride, for molecular biology

    Salmiac, for molecular biology

    		 TGF-beta/Smad Apoptosis Chloride Channel Neurological Disease Cancer
    Ammonium chloride (Salmiac), for molecular biology is an inhibitor of Slc26a4 and SMAD2. Ammonium chloride, for molecular biology reduces the protein expression level of Slc26a4 in lung tissue, and attenuates ozone-induced increases in proinflammatory cytokines, inflammatory cells, pulmonary resistance, goblet cell hyperplasia, peribronchial inflammation and thiocyanate levels in mouse tissues and bronchoalveolar lavage fluid. Ammonium chloride, for molecular biology decreases the level of phosphorylated SMAD2, inhibits autophagy by reducing autophagy-related proteins, and enhances Cisplatin (HY-17394)-induced cancer cell apoptosis and DNA double-strand breaks. Ammonium chloride, for molecular biology also inhibits the TCA cycle, reduces ATP production, increases glucose utilization, regulates the levels of lactic acid, glutamic acid and ATP, and induces morphological degeneration of neuroblastoma cells. Ammonium chloride, for molecular biology can be used in studies related to ozone-induced airway injury, hepatocellular carcinoma, human cervical cancer, hepatic encephalopathy, Reye syndrome, epilepsy and neurodegenerative diseases .
    Ammonium chloride, for molecular biology
  • HY-W303895
    Luteolin monohydrate
    85+ Cited Publications

    		 Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite Others Cancer
    Luteolin (monohydrate) is the monohydrate of Luteolin. Luteolin (Luteoline), a flavonoid, is also a potent Nrf2 inhibitor. Luteolin has anti-inflammatory and anticancer properties, induces apoptosis and cell cycle arrest in multiple human cancer cell lines, including non-small lung cancer cells, and inhibits cell metastasis and angiogenesis .
    Luteolin monohydrate
  • HY-145312
    ATR-IN-4

    		ATM/ATR Cancer
    ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC50s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .
    ATR-IN-4
  • HY-N0855
    Alisol G

    Alisol-G; 25-Anhydroalisol A

    		 Carboxylesterase (CES) Bacterial HBV Infection Cancer
    Alisol G (25-Anhydroalisol A) is a human carboxylesterase 2 (hCES2) inhibitor with an IC50 of 3.85 μM. Alisol G exhibits cytotoxic activity against human cancer cells, antibacterial activity against Gram-positive strains, and anti-hepatitis B virus activity. Alisol G can be used in research related to lung cancer, breast cancer, prostate cancer, bacterial infections, and HBV infections .
    Alisol G
  • HY-P99516
    Vulinacimab

    HLX-06

    		 VEGFR Cancer
    Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .
    Vulinacimab
  • HY-147011
    FTO-IN-7

    		Fat Mass and Obesity-associated Protein (FTO) Cancer
    FTO-IN-7 (compound 17) is an inhibitor of FTO (fat mass and obesity-associated protein) with an IC50 of <1 μM. FTO-IN-7 can be used for the study of small-cell lung cancers and human bone marrow striated muscle cancer .
    FTO-IN-7
  • HY-148838
    c-Myc inhibitor 8

    		c-Myc Cancer
    c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research .
    c-Myc inhibitor 8
  • HY-N6060
    Ophiopogonanone B

    		Others Cancer
    Ophiopogonanone B is a homoisoflavone (compound 8) with an IC50 value of 15.42 μM for cytotoxicity against human lung cancer A5A9 cell line .
    Ophiopogonanone B
  • HY-177275
    c-Kit Receptor modulator-1

    		c-Kit Cancer
    c-Kit Receptor modulator-1 (Compound #22) is a c-Kit Receptor modulator. c-Kit Receptor modulator-1 can be used for malignant cancers such as canine mastocytoma, human gastrointestinal stromal tumor and small cell lung cancer research .
    c-Kit Receptor modulator-1
  • HY-W778423
    [Pt(DACH)(OH)2(ox)]

    Dihydroxy Oxaliplatin-Pt(IV)

    		 Drug Intermediate Cancer
    [Pt(DACH)(OH)2(ox)] is a Pt(IV) derivative of Oxaliplatin (HY-17371) with two axial hydroxido ligands, used as a precursor for synthesizing Pt(IV)-HDAC inhibitor prodrugs. [Pt(DACH)(OH)2(ox)] exerts cytotoxic activity against human cancer cells and accumulates in cancer cells for nuclear internalization and nuclear DNA platination. [Pt(DACH)(OH)2(ox)] can be used for the research of lung carcinoma, breast carcinoma, pancreatic carcinoma, colon carcinoma .
    [Pt(DACH)(OH)2(ox)]
  • HY-174336
    Survivin-IN-1

    		Survivin Apoptosis Cancer
    Survivin-IN-1 (Compound II₃) is a potent Survivin (a member of the Inhibitor of Apoptosis Protein family) inhibitor with an IC50 value of 8.1 μM against human lung cancer A549 cells and 9.0 μM against breast cancer MCF-7 cells. Survivin-IN-1 reduces Survivin protein levels and induces tumor cell apoptosis. Survivin-IN-1 is promising for research of malignant tumors such as lung cancer and breast cancer .
    Survivin-IN-1
  • HY-N16602
    (±)-Blephenanthrofuran B

    		Others Others
    (±)-Blephenanthrofuran B is a pair of enantiomers can be found in Bletilla striata. (±)-Blephenanthrofuran B shows no cytotoxic activity against human lung cancer A549 cells .
    (±)-Blephenanthrofuran B
  • HY-164487
    JBJ-08-178-01

    		Proteasome Cancer
    JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .
    JBJ-08-178-01
  • HY-178158
    SQS-IN-1

    		Farnesyl Transferase Apoptosis DNA/RNA Synthesis Cancer
    SQS-IN-1 is a squalene synthase (SQS) inhibitor. SQS-IN-1 exhibits potent and broad-spectrum anti-proliferative effects on both mouse and human lung cancer cell lines. SQS-IN-1 inhibits DNA replication and the cell cycle, causing mitochondrial hyperpolarization and inducing cell apoptosis. SQS-IN-1 inhibits cell migration and invasion. SQS-IN-1 can be used to the study of lung cancer .
    SQS-IN-1
  • HY-P991058
    Zimistobart

    BMS-986315

    		 Checkpoint Kinase (Chk) Cancer
    Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets NKG2A. Zimistobart can be used for the study of non-small cell lung cancer (NSCLC). The isotype control for Zimistobart can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    Zimistobart
  • HY-116639
    Javanicin

    		Bacterial Infection Cancer
    Javanicin is an antibacterial agent with certain antibacterial activity against pathogenic bacteria such as Bacillus megaterium, Staphylococcus aureus, Salmonella typhi, and Escherichia coli. Javanicin has weak cytotoxicity against the human lung cancer cell line .
    Javanicin
  • HY-N12200
    Mollicellin I

    		Others Cancer
    Mollicellin I (compound 1) is a depsidone. The growth inhibitory activity of Mollicellin I on human breast cancer (Bre04), human lung (Lu04) and human neuroma (N04) cell lines is not significant, with GI50s >10 μg/mL .
    Mollicellin I
  • HY-126803
    Saquayamycin B

    		Antibiotic Infection Cancer
    Saquayamycin B (compound 3) is a new angucycline antibiotic. Saquayamycin B has antitumor activities against a human lung (H-460) and a human breast cancer cell line (MCF-7) with GI50 values of 12.2 and 15.2 µM respectively .
    Saquayamycin B
  • HY-115385R
    Lumichrome (Standard)

    		Reference Standards Apoptosis MDM-2/p53 Akt β-catenin Nuclear Factor of activated T Cells (NFAT) NF-κB ERK p38 MAPK Metabolic Disease Cancer
    Lumichrome (Standard) is the analytical standard of Lumichrome. This product is intended for research and analytical applications. Lumichrome, a photodegradation product of Riboflavin, is an endogenous compound in humans. Lumichrome inhibits human lung cancer cell growth and induces apoptosis via a p53-dependent mechanism. Lumichrom is the inhibitor for AKT/β-catenin signaling pathway. Lumichrom is the inhibitor for AKT/β-catenin signaling pathway .
    Lumichrome (Standard)
  • HY-177482
    Pro-PTX

    		Drug Intermediate Neurological Disease Cancer
    Pro-PTX is a Pd-sensitive Paclitaxel (HY-B0015) prodrug with anticancer activity. Pro-PTX triggers intramolecular cyclization via Pd-catalyzed depropargylation to release active Paclitaxel (HY-B0015) and a non-toxic byproduct. Pro-PTX exhibits low cytotoxicity and antiproliferative activity in cancer cells and non-cancerous human cerebrovascular pericytes. Pro-PTX is applicable for research related to non-small cell lung cancer, glioblastoma and lung cancer .
    Pro-PTX

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: